ClinicalTrials.gg
CompletedNCT00038103Updated Feb 25, 2010Results posted

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

A Phase 2 interventional study of Exemestane and Celecoxib + Exemestane in Breast Neoplasms, sponsored by Pfizer. Completed at 20 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-25.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 23 studies testing celecoxib in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Celecoxib · Breast Neoplasms.

Enrollment
3rd of 19
111 · median 42
Started
2002
the only one that year
Phase 2
13 of 23
none open now
Registered
2nd of 23
by date

Among the 23 studies testing celecoxib in Breast Neoplasms, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2002, is one of 13 in phase 2, and was the 2nd registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 23 studies testing celecoxib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing celecoxib in Breast Neoplasms as a file.
02

Study summary

This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patient with or cytologically confirmed breast cancer having progressed on Tamoxifen.
  • Advanced disease: patients with advanced breast carcinoma with disease progression who had progressed/ following > 8 weeks of treatment with Tamoxifen for advanced disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months depending on receptor status; or progressed within 12 months from completion of treatment with Tamoxifen.
  • at least one

Exclusion criteria

Exclusion Criteria:

  • More than one previous chemotherapy and/or more than one hormonotherapy for advanced disease.
  • Previous hormonotherapy for advanced disease other than Tamoxifen.
  • Myocardial infarction within previous 6 mo
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Active comparator
    1.

    Drug: Exemestane

  • Experimental
    2.

    Drug: Celecoxib + Exemestane

Interventions

  • Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.

    Also known as: Aromasin

  • DrugCelecoxib + Exemestane

    Drug pages: CelecoxibStudies of CelecoxibCelecoxib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.

    Also known as: Celebrex, Aromasin

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Clinical Benefit

    Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation. Includes subjects with complete response (CR), partial response (PR), and long term disease stabilization (SD) for at least 24 weeks.

    Time frame: Baseline, Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV)

Secondary outcomes

  1. Number of Subjects With Objective Response

    Objective tumor response includes subjects with CR or PR according to RECIST.

    Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV

  2. Duration of Clinical Benefit

    Time from randomization date to first objective documentation of tumor progression or death due to tumor progression in the absence of previous documentation of tumor progression.

    Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV

  3. Duration of Objective Response (in Subjects With CR or PR)

    Time from the first objective documentation of response until the first objective documentation of tumor progression.

    Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks beyond 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV

  4. Duration of Long-Term SD

    Time from start of treatment until the first objective documentation of tumor progression or death due to tumor progression in the absence of previous documentation of tumor progression in subjects with long-term SD.

    Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months LSLV

  5. Time to Tumor Progression

    Time from randomization to first objective tumor recurrence or progression or death due to tumor progression in the absence of previous documentation of tumor progression.

    Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks beyond Week 24 up to Week 108 and every 24 weeks thereafter until 9 months following LSLV

  6. Time to Treatment Failure

    Time from randomization to first objective tumor recurrence or progression or death due to any cause or withdrawal from study treatment due to any reason, whichever was the earliest.

    Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV

  7. Survival

    Time from randomization to date of death (any cause).

    Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV or death

07

Results

Posted Feb 25, 2010

Participant flow

Participant flow — Overall Study
MilestoneExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Started5556
End of treatment5356
Completed00
Not completed5556
Withdrew: Adverse event56
Withdrew: Lack of efficacy4841
Withdrew: Withdrawal by subject03
Withdrew: Lost to follow-up03
Withdrew: Protocol violation02
Withdrew: Sponsor decision01
Withdrew: Randomized/never treated20

Outcome measures

PrimaryNumber of Subjects With Clinical Benefit

Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation. Includes subjects with complete response (CR), partial response (PR), and long term disease stabilization (SD) for at least 24 weeks.

Time frame:
Baseline, Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV)
Reported as:
Number · participants
Number of Subjects With Clinical Benefit
participantsExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Number of Subjects With Clinical Benefit2424
Statistical analysis
  • Exemestane (Exemestane Alone) · Clinical benefit rate: 49.0 · 95% CI 34.4 to 63.7Number of subjects showing clinical benefits out of the number of subjects in the evaluable set.
  • Combination (Exemestane + Celecoxib) · Clinical benefit rate: 47.1 · 95% CI 32.9 to 61.5Number of subjects showing clinical benefits out of the number of subjects in the evaluable set.
SecondaryNumber of Subjects With Objective Response

Objective tumor response includes subjects with CR or PR according to RECIST.

Time frame:
Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV
Reported as:
Number · participants
Number of Subjects With Objective Response
participantsExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Number of Subjects With Objective Response1112
Statistical analysis
  • Exemestane (Exemestane Alone) · Objective response rate: 22.4 · 95% CI 11.8 to 36.6Number of subjects showing objective response out of the number of subjects in the evaluable set.
  • Combination (Exemestane + Celecoxib) · Objective response rate: 23.5 · 95% CI 12.8 to 37.5Number of subjects showing objective response out of the number of subjects in the evaluable set.
SecondaryDuration of Clinical Benefit

Time from randomization date to first objective documentation of tumor progression or death due to tumor progression in the absence of previous documentation of tumor progression.

Time frame:
Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV
Reported as:
Median · weeks
Duration of Clinical Benefit
weeksExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Duration of Clinical Benefit49.1 (37.0 to 85.0)96.6 (37.0 to 147.0)
SecondaryDuration of Objective Response (in Subjects With CR or PR)

Time from the first objective documentation of response until the first objective documentation of tumor progression.

Time frame:
Baseline, Weeks 8, 16, 24, every 12 weeks beyond 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV
Reported as:
Median · weeks
Duration of Objective Response (in Subjects With CR or PR)
weeksExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Duration of Objective Response (in Subjects With CR or PR)32.7 (23.1 to 68.9)40.1 (28.3 to 169.1)
SecondaryDuration of Long-Term SD

Time from start of treatment until the first objective documentation of tumor progression or death due to tumor progression in the absence of previous documentation of tumor progression in subjects with long-term SD.

Time frame:
Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months LSLV
Reported as:
Median · weeks
Duration of Long-Term SD
weeksExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Duration of Long-Term SD52.9 (36.6 to 110.0)109.7 (36.6 to 147.0)
SecondaryTime to Tumor Progression

Time from randomization to first objective tumor recurrence or progression or death due to tumor progression in the absence of previous documentation of tumor progression.

Time frame:
Baseline, Weeks 8, 16, 24, every 12 weeks beyond Week 24 up to Week 108 and every 24 weeks thereafter until 9 months following LSLV
Reported as:
Median · weeks
Time to Tumor Progression
weeksExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Time to Tumor Progression20 (9.4 to 36.6)23.4 (16.3 to 36.9)
SecondaryTime to Treatment Failure

Time from randomization to first objective tumor recurrence or progression or death due to any cause or withdrawal from study treatment due to any reason, whichever was the earliest.

Time frame:
Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV
Reported as:
Median · Weeks
Time to Treatment Failure
WeeksExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Time to Treatment Failure18.1 (9.3 to 36.6)20.4 (14.9 to 34.6)
SecondarySurvival

Time from randomization to date of death (any cause).

Time frame:
Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV or death
Reported as:
Median · weeks
Survival
weeksExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Survival74.4 (57.7 to 101.4)73.9 (52.3 to 106.7)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exemestane (Exemestane Alone)———
Combination (Exemestane + Celecoxib)———
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
DyspnoeaRespiratory, thoracic and mediastinal disorders2/533/56
JaundiceHepatobiliary disorders2/530/56
VomitingGastrointestinal disorders2/530/56
AstheniaGeneral disorders2/530/56
PainGeneral disorders1/531/56
Post procedural complicationReproductive system and breast disorders1/530/56
DeathGeneral disorders1/531/56
AscitesGastrointestinal disorders1/530/56
NauseaGastrointestinal disorders1/530/56
General physical health deteriorationGeneral disorders1/531/56
Most frequent other events
Showing 10 of 171
Most frequent other events
EventExemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)
Back painMusculoskeletal and connective tissue disorders8/5310/53
CoughRespiratory, thoracic and mediastinal disorders9/534/53
VomitingGastrointestinal disorders8/532/53
Hot flushVascular disorders6/538/53
AnorexiaMetabolism and nutrition disorders7/533/53
Pain in extremityMusculoskeletal and connective tissue disorders7/535/53
DyspnoeaRespiratory, thoracic and mediastinal disorders4/537/53
AstheniaGeneral disorders4/536/53
ArthralgiaMusculoskeletal and connective tissue disorders5/536/53
DiarrhoeaGastrointestinal disorders3/535/53

Baseline characteristics

Age, Customized
Age, Customized(Participants)Exemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)Total
< 50 years20.016.036.0
50-64 years20.027.047.0
65-79 years15.012.027.0
=> 80 years0.01.01.0
Sex: Female, Male
Sex: Female, Male(Participants)Exemestane (Exemestane Alone)Combination (Exemestane + Celecoxib)Total
Female5556111.0
Male000.0
08

Study locations

20 sites
  • Pfizer Investigational Site
    Dallas, Texas 75204, United States
  • Pfizer Investigational Site
    Antwerpen, 2020, Belgium
  • Pfizer Investigational Site
    Bruxelles, 1000, Belgium
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Namur, 5000, Belgium
  • Pfizer Investigational Site
    Wilrijk, 2610, Belgium
  • Pfizer Investigational Site
    Porto Alegre, RS 90610-000, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01509-900, Brazil
  • Pfizer Investigational Site
    Sydney, Nova Scotia B1P 1P3, Canada
  • Pfizer Investigational Site
    Bogota, Bogota . DC, Colombia
  • Pfizer Investigational Site
    Cali, Colombia
  • Pfizer Investigational Site
    Hyderabad, Andhra Pradesh 500 082, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560 029, India
  • Pfizer Investigational Site
    Mumbai, Maharashtra 400 012, India
  • Pfizer Investigational Site
    Pune, Maharashtra 41101, India
  • Pfizer Investigational Site
    Mexico, Distrito Federal 07760, Mexico
  • Pfizer Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • Pfizer Investigational Site
    Lima, 11, Peru
  • Pfizer Investigational Site
    Lima, 34, Peru
  • Pfizer Investigational Site
    Manila, 1000, Philippines
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2002, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2002
First posted
May 30, 2002
Start
Jan 2002
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Feb 25, 2010
Last update
Feb 25, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00038103
Lead sponsor
Pfizer
First posted
May 30, 2002
Start date
Jan 2002
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Feb 25, 2010
Last update
Feb 25, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Exemestane

Start the discussion